Clinicians Develop Patient Identification Tool for RDN

The Taiwan Hypertension Society published a consensus statement about renal denervation (RDN), which included a helpful tool to identify RDN patients called RDN-i2.

- **R = Resistant**: Blood pressure (BP) uncontrolled under maximally tolerated doses of BP-lowering drugs of ≥3 classes for ≥1 months
- **D = Damage**: Hypertension-mediated organ damage (brain, heart, eye, blood vessel, and kidney) or established cerebro- or cardiovascular disease
- **N = Non-adherent**: - Patient preference and adherence explored on a regular basis - Inscrutable causes, such as inconvenience, forgetfulness, etc.
- **i = Intolerant**: Adverse events of BP-lowering drugs, like erectile dysfunction, asthenia, should be explored on a regular basis
- **2 = Secondary Causes**: - Definitely treated for ≥3 months but BP still uncontrolled - Irreversible causes, for example, renal parenchymal disease

"RDN should not be viewed as an anti-hypertensive treatment strategy only for patients with resistant hypertension."

2019 THS and TSOC Consensus Statement

---